Thermo Fisher will pay £256m for Alfa Aesar
Thermo CEO Marc Casper said: “The acquisition of Alfa Aesar enhances our existing portfolio of chemicals, solvents and reagents to support virtually every laboratory application – from research, to drug discovery and development, to production.”
“In addition, customers will benefit from greater access to these products through our extensive global commercial reach” he said.
A spokesman for the Thermo told us "we expect to complete the transaction by the end of the year and look forward to welcoming Alfa Aesar employees to our team."
Earlier this month Johnson Matthey said it was in advanced talks to sell Alfa Aesar and predicted that the deal would complete before the end of the year.
Commenting on the transaction, Johnson Matthey CEO Robert MacLeod said: "The divestment of the Research Chemicals business is a further step in delivering our long term strategy to focus the group on growth areas where we can apply our expertise in complex chemistry to create long term value for our shareholders."
According to Thermo the transaction is expected to be completed by the end of 2015.
Alfa Aesar - which generated revenue of £77m to the year ended March 31 2015 - will be integrated into Thermo Fisher’s Laboratory Products and Services Segment.
